A marked decrease in malaria-related deaths worldwide has been attributed to the
administration of effective antimalarials against Plasmodium falciparum, in particular …

Understanding and controlling the spread of antimalarial resistance, particularly to
artemisinin and its partner drugs, is a top priority. Plasmodium falciparum parasites resistant …

Antimalarial drug resistance, in particular resistance to Plasmodium falciparum, challenges
the treatment and control of malaria. In this Review, we summarise evolving patterns of …

Malaria parasites break down host haemoglobin into peptides and amino acids in the
digestive vacuole for export to the parasite cytoplasm for growth: interrupting this process is …

Almost 20 years have passed since the first reference genome assemblies were published
for Plasmodium falciparum, the deadliest malaria parasite, and Anopheles gambiae, the …

We report a large multicenter genome-wide association study of Plasmodium falciparum
resistance to artemisinin, the frontline antimalarial drug. Across 15 locations in Southeast …

The last two decades have seen a surge in antimalarial drug development with product
development partnerships taking a leading role. Resistance of Plasmodium falciparum to the …

Antimalarial drugs are key tools for the control and elimination of malaria. Recent decreases
in the global malaria burden are likely due, in part, to the deployment of artemisinin-based …

The widely used antimalarial combination therapy dihydroartemisinin+ piperaquine (DHA+
PPQ) has failed in Cambodia. Here, we perform a genomic analysis that reveals a rapid …

Plasmodium falciparum malaria, an infectious disease caused by a parasitic protozoan,
claims the lives of nearly a million children each year in Africa alone and is a top public …